Yahoo Finance Director Deepti Jain Acquires 25,000 Shares of Treace Medical Concepts Inc (TMCI)
On May 10, 2024, Deepti Jain, Director at Treace Medical Concepts Inc (NASDAQ:TMCI), purchased 25,000 shares of the company, as reported in a recent SEC Filing. This transaction has increased the insider's total shares in the company to 25,000, as the insider had not sold any shares in the past year.
Treace Medical Concepts Inc specializes in the design, manufacture, and marketing of orthopedic medical devices specifically targeting foot and ankle conditions. The company's innovative solutions aim to improve patient outcomes while simplifying procedures for healthcare providers.
The insider transaction history for Treace Medical Concepts Inc shows a pattern of more insider buying than selling over the past year, with 5 insider buys and 2 insider sells.
On the valuation front, shares of Treace Medical Concepts Inc were trading at $4.5 on the day of the insider's purchase. The company has a market cap of approximately $280.9 million. According to the GF Value, the stock has a price-to-GF-Value ratio of 0.14, suggesting that it is a Possible Value Trap, Think Twice.
The GF Value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted for the company's past performance and expected future business outcomes.
This insider buy could signal a strong belief in the company's future prospects or undervaluation based on internal metrics and assessments. Investors often look at such insider transactions as a sign of confidence from management or key stakeholders in the company's current valuation and future direction.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
